Anidulafungin

Drug Profile

Anidulafungin

Alternative Names: Ecalta; ECB; Eraxis; LY303366; PF-3910960; V-echinocandin; VEC; VER 002; VER-02

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Pfizer
  • Class Antifungals; Cyclic peptides
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Candidiasis

Highest Development Phases

  • Marketed Candidaemia; Candidiasis
  • No development reported Aspergillosis
  • Discontinued Pneumocystis pneumonia

Most Recent Events

  • 04 Oct 2017 Interim adverse events and efficacy data from a phase III trial in Candidiasis presented at the IDWeek 2017 (iDW 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 04 Aug 2015 Phase III development in Candidiasis/Candidaemia (In children, In adolescents) is ongoing in USA, Brazil, Canada, Greece, Germany, France, Portugal, Spain, Italy, South Korea, Russia and Taiwan (NCT00761267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top